Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like Effective Immediately: OncoSec Names Former Advaxis Exec as New CEO November 7, 2017 The Lone 3 Big Pharmas That Will Gain Market Share Over the Next Few Years November 6, 2017 Illumina Leaves Mission Bay for New Campus in the Peninsula February 15, 2018